Category Archives: Genetics

New era of beef genetics at Genus ABS – Farming Life

A decline in the Northern Ireland suckler herd numbers and more emphasis on beef from the dairy herd has highlighted the need for specialised and targeted breeding programs to ensure success in both areas.

In addition, the importance of differentiated and tailored genetics for Northern Ireland livestock has been highlighted as one of the aims of the AgriFood Strategy Boards recommendations to government, while current research work by AFBI, in conjunction with commercial partners is investigating the use of synchronised breeding in the suckler herd in order to improve calving interval and quality of calves.

Always in the lead when it comes to new breeding initiatives, Genus ABS has introduced a new era (NuEra) of beef genetics that encompasses all available beef breeding programs, evaluations and indexes which will open up a whole new breeding concept for beef farmers. This new era of genetic improvement will produce more value for the entire chain including producers, processors and retailers according to Ervin McKinstry, Ireland Manager for Genus ABS.

He said: NuEra Genetics will improve the genetic gene pool, improve production efficiencies and increase sustainability thus benefitting the entire beef production and retailing chain. While this is a world wide program it is particularly relevant to Northern Ireland in that the number of suckler cows has declined over recent years and a considerable number of beef animals are derived from the dairy herd.

Ervin added: We need to have genetic programs that are specifically tailored for the dairy herd to produce the type of animal that will meet the needs of the retailer and consumer. In addition, using targeted beef genetics on lower ranking dairy cows adds a significant revenue stream to the dairy business. We also need to have more targeted genetics in the suckler herd to suit the environment, farming systems and the specific market that the farmer is supplying.

According to Ervin, NuEra Genetics symbolizes the next chapter in the history of Genus ABS beef genetics. A chapter that is focused on providing robust improvement and delivering value to customers throughout the beef supply chain. They will benefit through increased efficiency leading to greater profitability and ultimately a more sustainable system.

The Genus ABS Beef Calving Survey and Beef Advantage will be marketed under NuEra Genetics going forward, as both are proprietary to Genus ABS. Customers should look for new products to be released under the NuEra Genetics brand in the coming months. Such products include proprietary indexes tailored to specific customer needs, making it easier for customers to select the most efficient and profitable genetics.

For further information on NuEra Genetics contact your Genus ABS representative or phone the office on 028 3833 4426.

Read more here:
New era of beef genetics at Genus ABS - Farming Life

Increased Confidence Earns Myriad Genetics An Upgrade – Benzinga

Deutsche Bank upgraded Myriad Genetics, Inc. (NASDAQ: MYGN), as it believes the risk/reward is now balanced following the company below-consensus sales and earnings per share guidance for 2018.

The firm upgraded the rating from Sell to Hold, with the price target at $28.

At time of writing, shares of Myriad Genetics were rallying 3.19 percent to $28.75.

Analyst Dan Leonard said he was earlier concerned that the Street numbers were too high and didn't sufficiently reflect downside in the company's Hereditary Cancer Testing, or HTC, business, which accounts for 74 percent of the total sales. The company's sales guidance for 2018 was 4 percent below the Street estimates at the midpoint, the analyst noted.

See also: August PDUFA Dates: Biotech Investors Stay Tuned To A Month Of Plenty

Deutsche Bank believes the price erosion in the core hereditary cancer testing business is likely to be metered post 2019, given that cost of HCT isn't a large portion of spend at any given payer.

Additionally, the firm noted that payers have historically used prior authorization as the primary lever to limit genetic testing spend, rather than price. The firm said payers may not prefer discriminating between providers, given the challenge posed by getting acquainted with the evolving medical practice, the firm said.

Meanwhile, Deutsche Bank also indicated Myriad Genetics is able to convince payers that the other HCT options aren't perfect substitutes for its tests due to its variant database and the FDA approved status of its BRCAnalysis test.

The firm also sees opportunity for volume gains to continue.

Deutsche Bank believes the Street estimates through 2020 now appear more appropriate, while opining that its estimates are largely in line save some timing differences.

"We would be more constructive on greater conviction in MYGN's efforts outside of hereditary cancer testing and/or greater volume growth in hereditary cancer testing," the firm concluded.

View More Analyst Ratings for MYGN View the Latest Analyst Ratings

Posted-In: Deutsche Bank - Dan LeonardAnalyst Color Upgrades Analyst Ratings Best of Benzinga

2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Link:
Increased Confidence Earns Myriad Genetics An Upgrade - Benzinga

East Yorkshire company to supply beef genetics to a French co-operative – Darlington and Stockton Times

AN EAST Yorkshire company has agreed an initial five-year contract to supply beef genetics to a French co-operative.

The Stabiliser Cattle Company (SCC) of Givendale, near Pocklington, York, has signed an agreement for Bovinext to be the exclusive provider of Stabiliser genetics to French breeders.

Stabilisers continue to be the fastest growing breed of cattle in the UK, and their moderate, easy calving frame with high fertility and efficient feed conversion traits opened the gates to the new international export market.

Laurent Rouyer, president of Bovinext, said French farmers are increasingly aware of their native breeds becoming too big for the market and not delivering consistent, high-marbled meat quality for which there is growing consumer demand.

He said these factors, and the desire to increase farm margins had generated a lot of excitement on the French market with 50 breeders already making plans to use Stabiliser semen and embryos.

The initial five year contract is set to deliver genetics through extensive semen sales and embryo transfers, with an initial target of 1,000 Stabiliser breeding females in France.

Live cattle exports will also be a crucial component of meeting the target and the first set of breeding heifers will arrive in France in November according to SCC technical manager Dr Duncan Pullar.

French born Stabiliser calves will be included in the UK EBV evaluation programme to ensure continued genetic progress and on-going links with Stabilisers in the UK.

Dr Pullar said: Including the performance data generated in France in our UK evaluation is going to make a good project even stronger because French breeders will be able to compare their cattle with those in the UK and make good breeding decisions based on the same EBVs.

AHDBs French export manager Rmi Fourrier, who facilitated the agreement, said it was a win-win situation in that it supports UK farmers while showcasing quality beef and genetics the UK has to offer.

Richard Fuller, SCC business development director, predicted the agreement would increase future demand for UK beef genetics.

He said: The potential in France is enormous for UK beef genetics by working with Bovinexts million-cow network.

French breeds swept into the UK in the 1960s and 1970s because they outperformed the native breeds on growth and yield.

How exciting now that we can export Stabiliser beef cattle genetics that excel in growth, yield and eating quality to the French! We fully expect more demand for our genetics.

See original here:
East Yorkshire company to supply beef genetics to a French co-operative - Darlington and Stockton Times

Can genetics refute white supremacist theories? – BioEdge

This weeks headlines were filled with news from Charlottesville, Virginia, after a white supremacist drove his car into a crowd of people opposing a march of supremacists and noe-Nazis, killing one woman and injuring many others. Which leads one to ask: how white are American white supremacists?

For most of them, the most convincing way to prove their whiteness is DNA tests from companies like 23andMe.com and Ancestry.com. To their consternation, the results are often not what they expected. White supremacist Craig Cobb was outed on daytime TV in 2013 as 86 percent European, and 14 percent Sub-Saharan African.

Whats interesting is how the white supremacists respond to these disconcerting test results. Aaron Panofsky and Joan Donovan, sociologists at UCLA, studied online discussions of genetic ancestry test results on the white nationalist website Stormfront. They found that the participants used fairly sophisticated reasoning to challenge the results and regain their whiteness.

Cobb, for instance, denounced his test as statistical noise and described it as a Jewish conspiracy to spread junk science whose intent is to defame, confuse and deracinate young whites on a mass levelespecially males. Using a test from another company he was able to claim that he was European, apart from a 3% Iberian thing.

Panofsky and Donovan conclude that genetics cannot refute racist views. Even though mankind probably came from Africa and even though the notion of racial purity is absurd, racists can manipulate and interpret data for their own purposes. They conclude:

clear communication, simple forms of education, and collective denunciations of scientific misuses, scientists preferred forms of anti-racist action, are insufficient for the task. Challenging racists public understanding of science is not simply a matter of more education or nuance, but may require scientists to rethink their research paradigms and reflexively interrogate their own knowledge production.

Continue reading here:
Can genetics refute white supremacist theories? - BioEdge

Hendrix Genetics opens new hatchery in Grand Island | Agriculture … – Grand Island Independent

Gov. Pete Ricketts was on hand Tuesday to help celebrate the opening of Hendrix Genetics new hatchery in Grand Island.

The $18.5 million facility at 2325 W. Schimmer Drive covers 20 acres in the northeast section of Grand Islands Platte Valley Industrial Park-East.

Along with Ricketts, representatives of Hendrix Genetics from Europe and North America were in attendance. The new hatchery operation will serve 10 percent of the U.S. market demand.

It is a fantastic state-of-the-art facility for this hatchery, said Ricketts, who toured the facility with Nebraska Department of Agriculture Director Greg Ibach.

The governor called the plant a great example of value-added agriculture and how we are going to grow Nebraska.

It is not only a $20 million investment here that will create between 40 to 50 jobs, but it is going to allow area farmers to put up these barns for the eggs that will supply this hatchery and a diversified revenue stream for those farmers who are participating, Ricketts said.

The farmers who are putting up the barns to raise the eggs for Hendrix Genetics will be feeding their layers feed thats coming from out state, he said.

It is an example of how we take a commodity and add value to them in order to grow our state and grow our economy, Ricketts said.

By continuing to focus on value-added agriculture, like with the Hendrix Genetics facility, he said, jobs will be created that will allow the next generation of Nebraskans to remain in the state.

Attending the ceremony was Antoon van den Berg, chief executive officer of Hendrix Genetics.

This is a showcase for the company, van den Berg said.

He said having the facility in Nebraska is important.

It is a big important and high-value market, van den Berg said.

Currently, Hendrix Genetics has 25 percent of the U.S. market.

We needed the facility here to grow markets, van den Berg said.

After searching throughout the U.S. for a location for a new hatchery, he said, the company found that the Grand Island location fitted its goal to expand its market share because of the communitys central location in the U.S. and the fact that it isnt located in a densely populated area for biosecurity.

I think Nebraska has done an excellent job to motivate us to build here, van den Berg said.

Dave Taylor, president of the Grand Island Area Economic Development Corp., said the Hendrix Genetics plant will add 43 jobs and represents a more than $40 million infusion to the area economy.

Taylor said the facility will not only have an economic impact on Grand Island, but Central Nebraska as a whole.

In addition to the main hatchery in Grand Island, 11 outlying barns to support the facility are planned for development within 100 miles of the facility, with eight already in progress or complete.

The barns are located in Buffalo, Fillmore, Franklin, Nuckolls, Merrick, York, Clay and Gosper counties.

It is a very exciting time for us and for our ag economy with the addition of poultry, Taylor said.

The Grand Island Area Economic Development Corp. played a large role in recruiting Hendrix Genetics to Grand Island.

Just being able to hire 43 new people to the area is really exciting, Taylor said.

Serv Hermans, Hendricks Genetics managing director for layers, said the company is pleased to be opening our state-of-the-art layer hatchery in Grand Island.

The city and state offered a number of benefits for our operations, including proximity to our customers and feed sources, strong partnership with local representatives and community incentives, Hermans said. The opening is just the next step in building a long and positive relationship with the Grand Island people and establishing our production hub here in Nebraska to serve the U.S. market with high-quality products.

Hermans said the Grand Island plant will produce enough chickens to produce 10 billion eggs or about 25 eggs per person in the U.S. In 2016, the U.S. consumption was estimated at 268.4 eggs per person.

Hendrix has two other hatcheries in the U.S.

We feel extremely proud here today in this new building so we can contribute to feeding the world, Hermans said.

Hendrix Genetics is a privately held, international multi-species breeding company with activities in layer, turkey, swine, traditional poultry and aquaculture breeding. The layer business unit of Hendrix Genetics breeds pure line layers in seven R&D centers, located in Canada, France and the Netherlands, and produces parent stock of day-old chicks in five main production centers, located in Canada, Brazil, Netherlands, France and Indonesia. Hendrix Genetics is headquartered in Boxmeer, the Netherlands.

The company has more than 2,800 employees and leads the world in turkey, layer and trout breeding. It also has a growing share in swine, salmon and guinea fowl breeding worldwide.

Also attending the ceremony was Doug Metzler, general manager for layers for Hendrix, and Peter Mumm, Hendrix director of business development.

This is a huge development for us, said Metzler. It is a wonderful opportunity. It signals a growing business that is exciting and a great opportunity to be involved in distribution in a new area of the country for us.

He said the Grand Island facility will produce layer hens that will be sold to Hendrix customers to produce table eggs and eggs for the food product industry.

The fertile eggs will come from the 11 area farmers that Hendrix has contracted with as soon as they are hatched. Hendrix provides the producers with the breeding stock.

Once the freshly laid eggs come to the plant, theyre incubated for 21 days in the facility. When the baby chicks are hatched, they are distributed to Hendrix customers for their own operations to produce eggs for the industry.

Read the original here:
Hendrix Genetics opens new hatchery in Grand Island | Agriculture ... - Grand Island Independent

Fluidigm (FLDM) Licenses CFTR Assay From Baylor Genetics … – Nasdaq

South San Francisco, CA-based Fluidigm Corporation FLDM , a leading player in the analysis of single cells and industrial application of genomics, recently announced that it has entered into a licensing agreement with Baylor Genetics.

Per the agreement, Fluidigm licensed the rights to commercialize the CFTR (cystic fibrosis transmembrane conductance regulator) library prep assay developed by Baylor Genetics for research purposes. This would be used with its proprietary Juno automated microfluidic system. The targeted library prep assay enables accurate identification of variants from each of the 27 exons in the CFTR gene and selected intronic regions. When combined with Fluidigm microfluidics, this solution has the potential to significantly simplify complex labor-intensive laboratory workflows and improve the efficiency of CFTR sequencing. This would invariably improve the efficiency of its Juno automated microfluidic system and help the company to capture a considerable market share.

Next-generation sequencing offers a more comprehensive approach to CFTR genetic analysis by allowing a complete view of the sequence. Targeted sequencing library prep workflows, however, can be very labor-intensive. With the application of Fluidigm automated microfluidics technology, library preparation can be streamlined to provide significant efficiencies.

Over the past one month, Fluidigm has underperformed the broader industry . The stock has shed 7.1%, compared with the industry's decline of 3.1%.

Fluidigm develops, manufactures and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single cell genomics. The company caters to leading academic institutions, clinical research laboratories and pharmaceuticals, biotechnology and agricultural biotechnology companies worldwide.

Zacks Rank & Key Picks

Currently, Fluidigm has a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Edwards Lifesciences Corp. EW , Lantheus Holdings, Inc. LNTH and Align Technology, Inc. ALGN . Edwards Lifesciences and Align Technology sport a Zacks Rank #1 (Strong Buy), while Lantheus Holdings carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .

Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has gained around 3.2% over the last three months.

Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has gained 66.1% over the last six months.

Align Technology has a long-term expected earnings growth rate of 26.6%. The stock has rallied roughly 29.6% over the last three months.

4 Surprising Tech Stocks to Keep an Eye on

See Stocks Now>>

Edwards Lifesciences Corporation (EW): Free Stock Analysis Report

Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report

Align Technology, Inc. (ALGN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Read more from the original source:
Fluidigm (FLDM) Licenses CFTR Assay From Baylor Genetics ... - Nasdaq

What is Genetics?

Genetics is the study of heredity. Heredity is a biological process where a parent passes certain genes onto their children or offspring. Every child inherits genes from both of their biological parents and these genes in turn express specific traits. Some of these traits may be physical for example hair and eye color and skin color etc. On the other hand some genes may also carry the risk of certain diseases and disorders that may pass on from parents to their offspring.

The genetic information lies within the cell nucleus of each living cell in the body. The information can be considered to be retained in a book for example. Part of this book with the genetic information comes from the father while the other part comes from the mother.

The genes lie within the chromosomes. Humans have 23 pairs of these small thread-like structures in the nucleus of their cells. 23 or half of the total 46 comes from the mother while the other 23 comes from the father.

The chromosomes contain genes just like pages of a book. Some chromosomes may carry thousands of important genes while some may carry only a few. The chromosomes, and therefore the genes, are made up of the chemical substance called DNA (DeoxyriboNucleic Acid). The chromosomes are very long thin strands of DNA, coiled up tightly.

At one point along their length, each chromosome has a constriction, called the centromere. The centromere divides the chromosomes into two arms: a long arm and a short arm. Chromosomes are numbered from 1 to 22 and these are common for both sexes and called autosomes. There are also two chromosomes that have been given the letters X and Y and termed sex chromosomes. The X chromosome is much larger than the Y chromosome.

The genes are further made up of unique codes of chemical bases comprising of A, T, C and G (Adenine, Thymine, Cytosine and Guanine). These chemical bases make up combinations with permutations and combinations. These are akin to the words on a page.

These chemical bases are part of the DNA. The words when stringed together act as the blueprints that tells the cells of the body when and how to grow, mature and perform various functions. With age the genes may be affected and may develop faults and damages due to environmental and endogenous toxins.

Women have 46 chromosomes (44 autosomes plus two copies of the X chromosome) in their body cells. They have half of this or 22 autosomes plus an X chromosome in their egg cells.

Men have 46 chromosomes (44 autosomes plus an X and a Y chromosome) in their body cells and have half of these 22 autosomes plus an X or Y chromosome in their sperm cells.

When the egg joins with the sperm, the resultant baby has 46 chromosomes (with either an XX in a female baby or XY in a male baby).

Each gene is a piece of genetic information. All the DNA in the cell makes up for the human genome. There are about 20,000 genes located on one of the 23 chromosome pairs found in the nucleus.

To date, about 12,800 genes have been mapped to specific locations (loci) on each of the chromosomes. This database was begun as part of the Human Genome Project. The project was officially completed in April 2003 but the exact number of genes in the human genome is still unknown.

Reviewed by April Cashin-Garbutt, BA Hons (Cantab)

Read the original post:
What is Genetics?

White Supremacists Are Using Genetic Ancestry Tests For A Creepy Purpose – HuffPost

Its a marketing trope often repeated in viral,feel-good commercials for genetic ancestry tests: If we only knew just how related we all were, even distantly, then prejudice and racism would cease to exist.

But new research at the University of California, Los Angeles, finds the opposite: White supremacists do not especially care what their genetic ancestry tests show, if they reveal anything that doesnt conform with their claimed white heritage. At the same time, these genetic tests may actually be exciting to white supremacists because it gives them a scientific argument for the diversity of the European race, which helps them appropriate the language of diversity and multiculturalism for hateful purposes.

The findings, presented at the American Sociological Association this week and to be published in a forthcoming journal article, are a sober reminder that it takes a lot more than genetic proof of multiethnic ancestry to dissuade hard-core racists from their hateful ideology. In fact, the tests may bolster some of their beliefs.

We cant rely on genetic information to turn white nationalists away from their views, researcher Aaron Panofsky wrote in an email to HuffPost. I saw a tweet that said we should crowdfund [genetic ancestry tests] for these guys and that would end the movement. I think that is completely wrong and the genetics cant save us.

In a video posted on the Ancestry.com YouTube page, one participant says, There would be no such thing as, like, extremism in the world if people knew their heritage like that.

Genetic ancestry tests require people to spit into tubes and send the saliva samples to a lab for analysis. A few weeks later, they are directed to a website that reveals their genetic heritage. All genetic ancestry companies compare a persons genome with a proprietary database of reference populations, and show percentages of DNA defined racially, ethnically, continentally, or by modern nation-states. So, a person may be 87 percent East Asian in one companys test, but 67 percent Chinese in another companys test. The services also analyze mitochondrial DNA passed down from the mother and father to assess how ancestors may have migrated over time.

For genealogy hobbyists, its a good way to search for long-lost relatives to complete the family tree. Recent news articles, however, have highlighted a dark side of these tests, as they can also reveal long-hidden genetic secrets, like true paternity or the fact that babies may have been switched at birth.

While genetic ancestry tests have the veneer of scientific accuracy, they have come under attack by scientists. As Panofsky and Donovan put it in their forthcoming paper, the tests trade on the authority of science but do not adhere to scientific standards of openness and accountability. Further, there are no industry standards or uniformity. Each company has their own trademarked panel of population samples, algorithms and DNA markers, and consumers may get different or even conflicting results from company to company. And this confusion doesnt even get into the messiness of the history of human civilization: What would 75 percent Spanish mean with the nation-state of Spains history of invasions, wars and immigration patterns?

To examine how white supremacists use these tests, Panofsky and co-author Joan Donovan scoured the discussion boards of Stormfront, the oldest online forum for white supremacists, and identified 153 people who had posted the results of their genetic ancestry tests for comment.

Fifty-three of the people who posted were happy about good news that confirmed their European heritage, 49 posted their results because they were confused or disappointed, and 51 posted results without comment, although other forum members were free to discuss them.

Panofskys first observation was that, despite the promises of those sappy viral videos, not a single person renounced their hateful beliefs in reaction to their test results. He also was surprised that Stormfront members were willing to post their bad news results, even though the rules of membership are that people must have all-white, non-Jewish ancestry.

For some white supremacists who found links to Jewish or other non-European people groups, feedback from the forum ranged from never breed, to more gentle assurances that as long as they didnt see Jew when they looked in the mirror, they could claim whiteness.

Finally, Panofsky observed that members were having in-depth discussions in an attempt to explain away undesirable ancestry by suggesting the test itself was either invalid (a Jewish conspiracy to confuse white people, for example) or the tests methodology and statistical analysis were flawed.

They have very sophisticated interpretations that are based on statistical, genetic, and historical reasoning, Panofsky said. The conclusions and interpretations they make are often not the ones professional geneticists, biological anthropologists, and historians would make, but these interpretations are not ignorant or uneducated.

Perhaps most disturbing, some white supremacists are taking news of their heritage from multiple European countries and using it to create a pallete of diversity that doesnt include people of color.

A persons test might come back 30 percent English, 20 percent Danish, 40 percent German, etc., and this looks like great diversity within Europeans without people of color being involved, Panofsky explained. Already some white nationalists portray white people as the true people of color (red hair, blond, brown, and black hair; blue, green, and brown eyes; pale to olive skin etc.), while seeing non-whites as all the same.

Regardless of how white supremacists see it, the historical definition ofwhiteness is a socially constructed, ever-shifting categorization. In the 19th century, superior whites were of Saxon stock, and didnt include the Irish, Italian or Eastern European Jews. Over time, some of these groups gained entry into whiteness,while others didnt.

Now, it appears that genetic ancestry tests complicate whiteness even further and not in the way that genetic ancestry testing companies anticipated.

America does not do a good job of tracking incidents of hate and bias. We need your help to create a database of such incidents across the country, so we all know whats going on. Tell us your story.

Excerpt from:
White Supremacists Are Using Genetic Ancestry Tests For A Creepy Purpose - HuffPost

Buy Gilead Sciences, JD.Com And Sell Atossa Genetics – Top RSI Trades For Today – Amigobulls

Day Trading Ideas, RSI overbought/oversold signals - Buy Gilead Sciences, Inc. (GILD) stock, JD.Com Inc(ADR) (JD) stock and sell Atossa Genetics Inc (ATOS) stock.

Here is a summary of today's top day trading ideas based on popular momentum indicator Relative Strenght Index (RSI). The RSI indicator can be used to identify buy/sell signals in the market and today's most popular stocks flashing buy/sell signals using RSI indicator include Foster City, California-basedbiotech company Gilead Sciences (NASDAQ:GILD), Chinese e-commerce company JD.com (NASDAQ:JD) and Seattle-based healthcare firmAtossa Genetics (NASDAQ:ATOS). If you want to see the complete set of technical tradingideas for todaycheck them out here.

Shares of Gilead Sciences have failed to sustain the rally after theQ2 2017 earnings release in the last week of July. In the month of August, GILD stock has gradually trended downwards and is down nearly 5%. Investors would be hoping for a rebound soon, as the companyseems to be getting things sorted, posting better than expected earnings in the second quarter. The GILD stock may soon end its downward trend, as theas the stock is in oversold territory. The RSI indicator is flashing an oversold signal for Gilead stock. The RSI value of the stock has fallen to 27.22, which is below the commonly use oversold RSI measure of 30. The rebound in Gilead shares couldget a further boost by the fact that the share price is very close to the lower Bollinger Band, implying that the indicator could flash an oversold signal as well. A rebound in Gilead shares is most likely around the corner.

Shares of JD.Com have had an amazing year, rising by a whopping 89% until last week. From August 9th, JD stock has been trending downwards going into its earnings. In spite of the massive correction of more than 14%, the stock is up more than 60% in the Year-to-Date. JD.com delivered better than expected results in its Q2 earnings, but the downward pressure increased on account of widened Q2 losses. However, it might be time to buy JD stock again. The fundamental story of JD has not changed much, as the company has forecasted strong revenue growth of36% to 40%for the third quarter. Popular momentum indicators like RSI and Bollinger Bands are both flashing an oversold signal. The RSI value of the stock stands at 29.87, just below the common oversold threshold measure of 30. For JD.Com stock, the Bollinger Bands indicator is also flashing an oversold signal. The share price of the company has already fallen below the lower Bollinger Band to flash an oversold signal. This further increases the probability that JD stock may soon resume its uptrend. The combination of the above two signals is considered as a strong signal.

Looking for fundamentally better tech stocks? Check out Amigobulls'top stock picksfrom the tech sector, which have beaten the NASDAQ by over 140%. Interested in automotive stocks? Then, we also have ourtop picks from the auto sector, which have beaten the S&P 500 by a massive 234%.

Originally posted here:
Buy Gilead Sciences, JD.Com And Sell Atossa Genetics - Top RSI Trades For Today - Amigobulls

Seattle Genetics’ Adcetris Granted Priority Review by FDA – Nasdaq

Seattle Genetics, Inc. SGEN announced that the FDA has accepted its supplemental Biologics License Application (BLA) for Adcetris (brentuximab vedotin) in patients with cutaneous T-cell lymphoma (CTCL). Additionally, the FDA granted Priority Review for the application and has set a target action date of Dec 16, 2017.

Adcetris is the only marketed product at Seattle Genetics. The drug is approved for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma (sALCL) in the U.S., the EU and Japan. It is also approved in the U.S. for the treatment of patients suffering from classical Hodgkin lymphoma, who are at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.

Notably, shares of the company have declined 11.4% against the Zacks classified industry's gain of 7.4% on a year-to-date basis.

The submission of the supplemental BLA was mainly based on positive data from the phase III trial, ALCANZA and two phase II investigator-sponsored trials in patients with CTCL. Interestingly, the ALCANZA study achieved both the primary and secondary endpoints.

The study showed that CTCL patients treated with Adcetris had superior outcomes across all primary and secondary endpoints compared with patients in the control arm, who were treated with either methotrexate or bexarotene standard of care agents.

Furthermore, the FDA granted Breakthrough Therapy Designation (BTD) to Adcetris for the treatment of patients with CD30-expressing mycosis fungoides and primary cutaneous anaplastic large cell lymphoma, who require systemic therapy and have received one prior systemic therapy in November 2016.

Adcetris, generated revenues of $74.3 million, up 12.3% year over year in the second quarter of 2017 and is expected to generate sale in the range of $290 million to $310 million in the U.S. and Canada in 2017. Seattle Genetics is also working on expanding the drug's label which will be a further boost for the company's revenues.

Seattle Genetics, Inc. Price

Seattle Genetics, Inc. Price | Seattle Genetics, Inc. Quote

Zacks Rank & Stocks to Consider

Seattle Genetics currently holds a Zacks Rank #3 (Hold). Some better-ranked stocks in health care sector include Alexion Pharmaceuticals, Inc. ALXN , Regeneron Pharmaceuticals, Inc. REGN and Sanofi SNY . While Alexion and Regeneron sport a Zacks Rank #1 (Strong Buy), Sanofi holds Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .

Alexion Pharmaceuticals' earnings per share estimates have moved up from $4.55 to $4.77 for 2017 and from $5.49 to $6.43 for 2018 over the last 30 days. The company delivered positive earnings surprises in three of the trailing four quarters, with an average beat of 12.26%. The share price of the company has increased 11.7% year to date.

Regeneron's earnings per share estimates have increased from $10.52 to $13.81 for 2017 and from $12.10 to $14.54 for 2018 over the last 30 days. The company pulled off positive earnings surprises in two of the trailing four quarters, with an average beat of 6.29%. The share price of the company has increased 27.6% year to date.

Sanofi's earnings per share estimates have moved up from $3.20 to $3.31 for 2017 and from $3.36 to $3.38 for 2018 over last 30 days. The company came up with positive earnings surprises in three of the trailing four quarters, with an average beat of 5.10%. The share price of the company has increased 19.7% year to date.

One Simple Trading Idea

Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing and exclusive of fees, it can turn thousands into millions of dollars. This proven stock-picking system is grounded on a single big idea that can be fortune shaping and life changing. You can apply it to your portfolio starting today. Learn more >>

Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report

Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report

Seattle Genetics, Inc. (SGEN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Original post:
Seattle Genetics' Adcetris Granted Priority Review by FDA - Nasdaq